Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity

Mika Kato Kaneko, Akiko Kunita, Shinji Abe, Yuta Tsujimoto, Masashi Fukayama, Kaoru Goto, Yoshihiko Sawa, Yasuhiko Nishioka, Yukinari Kato

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Podoplanin is a platelet aggregation-inducing factor associated with tumor metastasis, malignant progression, and cancer stem cells. We produced a rat-human chimeric anti-podoplanin mAb, NZ-8, from rat anti-podoplanin mAb (NZ-1). Although both NZ-1 and NZ-8 possess high binding affinities and high neutralizing activities of platelet aggregation, the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity of NZ-8 were much higher than NZ-1. Furthermore, both NZ-1 and NZ-8 inhibited the growth of podoplanin-expressing tumors in vivo. Both NZ-1 and NZ-8 also suppressed hematogenous metastasis of podoplanin-expressing tumors. These results suggest that anti-podoplanin mAbs suppressed hematogenous metastasis by both neutralization and antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity activities. Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy.

Original languageEnglish
Pages (from-to)1913-1919
Number of pages7
JournalCancer Science
Volume103
Issue number11
DOIs
Publication statusPublished - Nov 2012
Externally publishedYes

Fingerprint

Anti-Idiotypic Antibodies
Neoplasm Metastasis
Antibodies
Platelet Aggregation
Neoplasms
Neoplastic Stem Cells
Immunotherapy
Growth
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. / Kaneko, Mika Kato; Kunita, Akiko; Abe, Shinji; Tsujimoto, Yuta; Fukayama, Masashi; Goto, Kaoru; Sawa, Yoshihiko; Nishioka, Yasuhiko; Kato, Yukinari.

In: Cancer Science, Vol. 103, No. 11, 11.2012, p. 1913-1919.

Research output: Contribution to journalArticle

Kaneko, MK, Kunita, A, Abe, S, Tsujimoto, Y, Fukayama, M, Goto, K, Sawa, Y, Nishioka, Y & Kato, Y 2012, 'Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity', Cancer Science, vol. 103, no. 11, pp. 1913-1919. https://doi.org/10.1111/j.1349-7006.2012.02385.x
Kaneko, Mika Kato ; Kunita, Akiko ; Abe, Shinji ; Tsujimoto, Yuta ; Fukayama, Masashi ; Goto, Kaoru ; Sawa, Yoshihiko ; Nishioka, Yasuhiko ; Kato, Yukinari. / Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. In: Cancer Science. 2012 ; Vol. 103, No. 11. pp. 1913-1919.
@article{ca4b4209f25741d1a1005d1c339fcf9c,
title = "Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity",
abstract = "Podoplanin is a platelet aggregation-inducing factor associated with tumor metastasis, malignant progression, and cancer stem cells. We produced a rat-human chimeric anti-podoplanin mAb, NZ-8, from rat anti-podoplanin mAb (NZ-1). Although both NZ-1 and NZ-8 possess high binding affinities and high neutralizing activities of platelet aggregation, the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity of NZ-8 were much higher than NZ-1. Furthermore, both NZ-1 and NZ-8 inhibited the growth of podoplanin-expressing tumors in vivo. Both NZ-1 and NZ-8 also suppressed hematogenous metastasis of podoplanin-expressing tumors. These results suggest that anti-podoplanin mAbs suppressed hematogenous metastasis by both neutralization and antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity activities. Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy.",
author = "Kaneko, {Mika Kato} and Akiko Kunita and Shinji Abe and Yuta Tsujimoto and Masashi Fukayama and Kaoru Goto and Yoshihiko Sawa and Yasuhiko Nishioka and Yukinari Kato",
year = "2012",
month = "11",
doi = "10.1111/j.1349-7006.2012.02385.x",
language = "English",
volume = "103",
pages = "1913--1919",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity

AU - Kaneko, Mika Kato

AU - Kunita, Akiko

AU - Abe, Shinji

AU - Tsujimoto, Yuta

AU - Fukayama, Masashi

AU - Goto, Kaoru

AU - Sawa, Yoshihiko

AU - Nishioka, Yasuhiko

AU - Kato, Yukinari

PY - 2012/11

Y1 - 2012/11

N2 - Podoplanin is a platelet aggregation-inducing factor associated with tumor metastasis, malignant progression, and cancer stem cells. We produced a rat-human chimeric anti-podoplanin mAb, NZ-8, from rat anti-podoplanin mAb (NZ-1). Although both NZ-1 and NZ-8 possess high binding affinities and high neutralizing activities of platelet aggregation, the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity of NZ-8 were much higher than NZ-1. Furthermore, both NZ-1 and NZ-8 inhibited the growth of podoplanin-expressing tumors in vivo. Both NZ-1 and NZ-8 also suppressed hematogenous metastasis of podoplanin-expressing tumors. These results suggest that anti-podoplanin mAbs suppressed hematogenous metastasis by both neutralization and antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity activities. Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy.

AB - Podoplanin is a platelet aggregation-inducing factor associated with tumor metastasis, malignant progression, and cancer stem cells. We produced a rat-human chimeric anti-podoplanin mAb, NZ-8, from rat anti-podoplanin mAb (NZ-1). Although both NZ-1 and NZ-8 possess high binding affinities and high neutralizing activities of platelet aggregation, the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity of NZ-8 were much higher than NZ-1. Furthermore, both NZ-1 and NZ-8 inhibited the growth of podoplanin-expressing tumors in vivo. Both NZ-1 and NZ-8 also suppressed hematogenous metastasis of podoplanin-expressing tumors. These results suggest that anti-podoplanin mAbs suppressed hematogenous metastasis by both neutralization and antibody-dependent cellular cytotoxicity/complement-dependent cytotoxicity activities. Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84868193994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868193994&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02385.x

DO - 10.1111/j.1349-7006.2012.02385.x

M3 - Article

VL - 103

SP - 1913

EP - 1919

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -